While economic uncertainty continues to be high, I want to invest in companies that are looking to solve today’s biggest problems. This leads me to a fast-growing player in healthcare: Abiomed Inc (NASDAQ: ABMD). Even at 14x revenue and 56x forward earnings, Abiomed is priced at a reasonable level where the company is expected to produce both double-digit revenue growth and steady margins for the next 5+ years, leading the company to be undervalued today and a great investment opportunity tomorrow.
Source: Company Website
Why Abiomed Trades At 14x Revenue
Abiomed provides solutions enabling the